COVID-19 in Patients With HIV
Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2
1 other identifier
observational
412
1 country
1
Brief Summary
Currently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2020
CompletedStudy Start
First participant enrolled
April 1, 2020
CompletedFirst Posted
Study publicly available on registry
April 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 28, 2022
CompletedMay 23, 2022
May 1, 2022
3 months
March 31, 2020
May 16, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
COVID-19 related death among patients with HIV and COVID-19
30 days
Secondary Outcomes (5)
Frequency of patients requiring hospital admissions
30 days
Frequency of patients requiring ICU admissions
30 days
Frequency of respiratory support use
30 days
Frequency of kidney injury
30 days
Frequency of liver injury
30 days
Interventions
No intervention, observational study
Eligibility Criteria
Patients with HIV disease who are diagnosed with COVID-19, inpatient or outpatient
You may qualify if:
- HIV disease
- Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Missouri-Columbia
Columbia, Missouri, 65212, United States
Related Publications (1)
Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, Llibre JM, Camazine M, Diaz-De Santiago A, Carlucci PM, Zacharioudakis IM, Rahimian J, Wanjalla CN, Slim J, Arinze F, Kratz AMP, Jones JL, Patel SM, Kitchell E, Francis A, Ray M, Koren DE, Baddley JW, Hill B, Sax PE, Chow J. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972. doi: 10.1093/cid/ciaa1339.
PMID: 32905581DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Month
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Clinical Medicine
Study Record Dates
First Submitted
March 31, 2020
First Posted
April 3, 2020
Study Start
April 1, 2020
Primary Completion
July 1, 2020
Study Completion
March 28, 2022
Last Updated
May 23, 2022
Record last verified: 2022-05